Dr. Mark R. Ling, M.D., PH.D.
Dermatology (Procedural Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- Duke University School of Medicine (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 965
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: Duke University School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Procedural Dermatology Physician primary
GA license 034647 -
Dermatology Physician
GA license 034647
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Epiphany Dermatology of Georgia, LLC (20 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 965
- Services billed
- 4,156
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 1,651 | 350 |
| Established patient office or other outpatient visit, 20-29 minutes | 900 | 690 |
| Destruction of precancer skin growth, 1 growth | 643 | 479 |
| Established patient office or other outpatient visit, 10-19 minutes | 280 | 246 |
| Biopsy of related skin growth, first growth | 209 | 181 |
| Destruction of skin growth, 1-14 growths | 206 | 188 |
| Established patient office or other outpatient visit, 30-39 minutes | 103 | 91 |
| Intermediate repair of wound of scalp, underarms, trunk, arms, or legs, 2.6-7.5 cm | 92 | 90 |
| Removal of cancer skin growth of body, arms, or legs, 1.1-2.0 cm | 77 | 75 |
| New patient office or other outpatient visit, 30-44 minutes | 34 | 34 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketoconazole Other prescribers in Newnan, GA | 205 |
| Triamcinolone Acetonide Other prescribers in Newnan, GA | 115 |
| Hydrocortisone Other prescribers in Newnan, GA | 94 |
| Doxycycline Monohydrate Other prescribers in Newnan, GA | 88 |
| Imiquimod | 56 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Newnan, GA | 54 |
| Mometasone Furoate Other prescribers in Newnan, GA | 53 |
| Mupirocin Other prescribers in Newnan, GA | 44 |
| Betamethasone Diprop Augmented (betamethasone/propylene glyc) | 37 |
| Enbrel Sureclick (etanercept) Other prescribers in Newnan, GA | 36 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 16 payments worth $370 in total to this clinician.
| AbbVie Inc. | $78.33 |
|---|---|
| E.r. Squibb & Sons, L.l.c. | $62.49 |
| Novartis Pharmaceuticals Corporation | $53.87 |
| Regeneron Healthcare Solutions, Inc. | $52.33 |
| Galderma Laboratories, L.P. | $47.98 |
| Leo Pharma Inc. | $34.65 |
| Botanix Sb Inc | $24.25 |
| Arcutis Biotherapeutics, Inc. | $15.74 |
| Food and Beverage | $317 |
|---|---|
| Education | $52.33 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. Oct 3, 2025 | Education DUPIXENT · IMMUNOLOGY AND INFLAMMATION · in-kind | $52.33 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $1,204 in research payments for these studies, mostly to the institutions running them.
- A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata
Eli Lilly and Company · Completed · NCT03570749
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.